New #JITC article: Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma bit.ly/3VHeckN Richard D Carvajal Omid Hamid MD Marcus Butler Alex Shoushtari, MD Jason Luke, MD, FACP

Roger Federer’s Commencement Address at Dartmouth yesterday might be the best speech he’s ever given. Amazingly articulate, funny, full of wisdom. Made me laugh and tear up. I’m so very proud to have had him as my idol for the past two decades. If you have 25 minutes to spare…

Did you see this data Paolo A. Ascierto presents @BMS Realtivity048 ASCO PD-1/LAG3/CTLA4 with OS curve !! Once again melanoma pushes the boundaries.... currently accruing this regimen +/-sarilumab #ASCO24 The Angeles Clinic NYU Langone Health MassGeneral Medicine Dana-Farber ascopubs.org/doi/10.1200/JC…

Listen to Omid Hamid MD, he's got the West Coast covered but Perlmutter Cancer Center at NYU Langone Health has this regimen +/sarilumab as a toxicity modulatory in New York City. State of the art regimen, but we are trying to improve it by making it less toxic. Our patients deserve no less.

Honored to have served as lead investigator on phase I study of botensilimab with expansion in MSS CRC; activity across cold tumors! Thank you to all co-authors and Agenus for the great collaboration. Gratitude to our amazing phase I team at USC Norris! nature.com/articles/s4159…

Proud to have contributed through our Phase 1 program The Angeles Clinic to ensure immunotherapy’s role in all solid tumors. #worktodo

Appreciate ASCO The ASCO Post allowing me to discuss the future with Bispecific ImmTAC Immunocore #ASCO24 work done at many institutes including Cedars-Sinai The Angeles Clinic #Brenetefusp currently enrolling phase 3 trial for cutaneous #melanoma #ASCO24 ascopost.com/videos/2024-as…

Despite its name, PRAME (or PReferentially expressed Antigen in #Melanoma) is common in multiple #cancers and is believed to play a role in tumor progression. Visit our Science page for more: immunocore.com/science #IMCRSharing

Stunning interim clinical trial data from Revolution Medicines... PFS = 8.1 mo in 2nd line KRAS G12-mutant metastatic #PDAC. OS not yet reached, but already more than a year! Benchmark PFS for this group is 2-3.5 months, behnchmark OS is 6.1-6.9. 1/

This is a turning point …..

In this episode of Targeted Talks, Omid Hamid, MD, (Omid Hamid MD) delves into the mechanism of action, supporting data, and approval of lifileucel for the treatment of advanced #melanoma. #MELSM | The Angeles Clinic targetedonc.com/view/advancing…

We’ve been cheering on Sydney McLaughlin-Levrone as she competes in the Summer Olympics, and last week, she brought home the gold in the 400m hurdles! Sydney is not only a champion on the track but also a powerful advocate for skin protection. Partnering with Neutrogena, our National Prevention

Listen to your friends, your family, your doctor, and a gold medal Olympian. Sydney McLaughlin-Levrone. We continue to fight to stop melanoma and search for cures but the best option is prevention The Angeles Clinic #worktodo

#ScienceSaturday The combination of anti-LAG-3 and anti-PD1 antibodies is U.S. FDA approved for patients with advanced #melanoma. But how is this combination working mechanistically? In a recent issue of Cell, 3 manuscripts shed light and suggest that PD-1 blockade

So sad to hear about the passing of Jeff Weber, a giant in the field of oncology. He was involved in the early days of cytokine and cell therapy and most recently led studies of personalized vaccines for melanoma patients. I originally worked with Jeff National Cancer Institute over 30 years ago.

Jeff Weber's career was not only filled with patient advocacy, leadership and achievement but punctuated by mentorship. I urge all fellows and junior faculty to find someone like Jeff – great friend, amazing mentor, brother, leader.  Jeff was on a trial call this Thursday at 7

🎉 🎉 Excited to share our latest research, now in Nature Cancer IrAEs can be associated with significant morbidity or mortality - our study suggests that targeting IL-17A CD4+ T cells could help manage these side effects better, and paves the way for 🎯 treatment approaches

Honored to be appointed Director of Experimental Therapeutics Cancer at Cedars-Sinai . Continuing work at The Angeles Clinic and Cedars-Sinai to bridge #phaseone #clinicaltrials to all patients. Justin Moyers Navid Hafez #clinicaltrialssavelives

Still reeling from the loss of Jeff Weber in our oncology Community. grateful for mentorship and programming especially the "Weber Rules" - there are 11 of 'em. My favorite is #11. "When all else fails, always talk to the patient." (yup) - more to come Hem-Onc Fellows Network ASCO

IBI363 PD-1/IL2α bispecific FDA Fast Track Designation for Advanced/Metastatic #Melanoma (DCR) 73.0%. Among 8 immuno-oncology (IO)–naive patients with #mucosalmelanoma, ORR was 75.0%, including 1 CR and 5 PRs. The DCR in this population was 100%. Innovent Melanoma Research Foundation